Full Description
The Myeloma MRD Panel by Flow Cytometry evaluates for the presence of minimal residual disease (MRD) in patients with previously diagnosed and treated multiple myeloma. The limit of detection is 0.01%. Markers include VS38c, CD19, CD20, CD27, CD45, CD56, CD81, CD117, CD138, CD269(BCMA), cKappa, and cLambda (12 markers).
Methodology
Flow Cytometry
Specimen Requirements
Bone marrow aspirate: 3-4 mL EDTA preferred. Sodium heparin tube is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
Storage and Transportation
Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
Turnaround Time
24-48 hrs (Global Only)
CPT Codes
88184(x1), 88185(x11), 88188(x1)